Clinical Trials
35 trialsNCT05283720 2026-05-06
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT06149286 2026-05-06
OLYMPIA-5
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT04712097 2026-05-05
Celestimo
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05888493 2026-04-17
LEDA
Novartis
Phase 3 Active not recruiting
NCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT07460362 2026-03-10
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Peking University Third Hospital
Phase 2 Recruiting
NCT02390869 2025-12-02
FIL_RENOIR12
Fondazione Italiana Linfomi - ETS
Phase 3 Active not recruiting
NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT05626322 2025-09-05
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Pfizer
Phase 1/2 Terminated
NCT07126236 2025-08-17
REPIFIR
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Recruiting
NCT06651853 2025-07-23
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06414148 2025-06-05
EpLCART
Peter MacCallum Cancer Centre, Australia
Phase 2 Recruiting
NCT04036448 2025-03-11
RevlimidPMS
Celgene
Completed
NCT03647124 2025-03-04
A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Celgene
Completed
NCT01199575 2024-08-15
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
University of California, San Diego
Phase 2 Completed
NCT00799513 2024-04-10
RV-NHL-PI351
IRCCS San Raffaele
Phase 2 Completed
NCT02341014 2024-04-04
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02600897 2023-12-26
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1/2 Completed
NCT05797948 2023-04-04
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT04113226 2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2 Unknown
NCT03302728 2022-05-19
EpiBrentlen
Peter MacCallum Cancer Centre, Australia
Phase 1 Completed
NCT01956695 2020-12-17
REVRI
Institut Curie
Phase 2 Completed
NCT01542918 2020-08-11
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
University of California, San Francisco
Phase 1 Completed
NCT04329130 2020-04-24
Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT01788189 2020-02-26
LeMLAR
University Hospital, Essen
Phase 1/2 Completed
NCT04109872 2020-02-05
Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Unknown
NCT01197560 2019-11-25
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Celgene
Phase 2/3 Completed
NCT00419250 2019-11-08
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
Celgene
Phase 1 Completed
NCT01729104 2019-10-22
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02060656 2019-09-19
LEGEND
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT00963105 2018-10-31
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Celgene
Phase 2 Completed
NCT02983097 2018-01-19
R²-DHAP
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 1/2 Terminated
NCT01121757 2016-09-12
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Duke University
Phase 2 Terminated
NCT01185262 2013-09-30
LLC-LENAR-08
MD Anderson International Spain SA
Phase 1 Completed
NCT00968331 2012-08-27
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
University of Bologna
Phase 2 Terminated